Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate

F. Montorsi, S. E. Althof, M. Sweeney, F. Menchini-Fabris, F. Sasso, F. Giuliano

Research output: Contribution to journalArticlepeer-review

Abstract

Treatment satisfaction, subanalysed by demographic variables, was evaluated in patients switching from successful intracavernosal prostaglandin E1 (PGE1) therapy to oral sildenafil citrate. The validated Erectile Dysfunction Inventory of Treatment Satisfaction questionnaire was administered at the end of PGE1 therapy and after 12 weeks of sildenafil treatment in a multicentre, open-label study. Men with erectile dysfunction (n = 176) who were switched from stable PGE1 therapy to sildenafil (25-100 mg) were equally satisfied with onset of action, duration of action, and confidence in ability to engage in sexual activity, but expressed greater overall treatment satisfaction with sildenafil (P1 injection, these data suggest that patients may be less likely to discontinue taking sildenafil treatment for their erectile dysfunction.

Original languageEnglish
Pages (from-to)444-449
Number of pages6
JournalInternational Journal of Impotence Research
Volume15
Issue number6
DOIs
Publication statusPublished - Nov 2003

Keywords

  • Erectile dysfunction
  • Intracavernosal injection
  • Prostaglandin E1
  • Sildenafil

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E1 intracavernosal injection therapy to oral sildenafil citrate'. Together they form a unique fingerprint.

Cite this